Primary Sjögren's Syndrome (pSS) is a chronic autoimmune disease that mainly affects the salivary and lacrimal glands, leading to dry mouth and eyes [1]. As the disease progresses, it causes systemic damage such as fatigue and anxiety. It can also cause lesions in target organs, such as joint pain, interstitial lung disease, and vasculitis. Primary Sjogren's syndrome is different from secondary Sjogren's syndrome, which is often associated with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc) [2], [3]. The global prevalence of primary Sjogren's syndrome ranges from 0.1 % to 0.6 %, mainly affecting middle-aged women with a male to female ratio of 1:9 [5]. The average age of initial diagnosis is 56 years old. Sjogren's syndrome seriously affects the quality of life of patients in the middle and later stages, and the main causes of death are infections, cardiovascular diseases, and malignant tumors of solid organs and blood systems [6].

At present, clinical treatment drugs for SS mainly include glucocorticoids, anti-inflammatory drugs, immunosuppressants, and biopolymer preparations [7]. However, the side effects of using these drugs remain a long-standing challenge for people. In recent years, more and more studies have found that Traditional Chinese medicine has good effects in treating SS [8].

SS has a high mortality rate in clinical practice. Fully understanding the mechanism of sepsis complicated with acute liver injury is of great significance for improving the prognosis of SS patients and selecting more accurate and effective treatment methods. Therefore, the purpose of this article is to search for new biological targets and intervention measures for SS.